When Oral Agents Stop Being Enough
Metformin and add-on orals no longer hold glucose targets.
- HbA1c > goal: Trigger for escalation (despite oral therapy)
- GLP-1 / Insulin: Two leading options (injectable step-up)
- 3 factors: Decision inputs (HbA1c, beta-cell, CV risk)
- Individualized fit: Goal (not one-size-fits-all)
Why escalation happens
Oral agents plateau; beta-cell decline continues over time.
Two divergent mechanisms
GLP-1 boosts endogenous insulin; exogenous insulin replaces it directly.
HbA1c Level Sets the Urgency
Higher HbA1c demands a more potent, predictable glucose-lowering tool.
- 7–8%: Mild elevation (either class often works)
- 9–10%: Marked elevation (insulin gains an edge)
- >11%: Severe elevation (insulin often preferred)
- 1–1.8%: GLP-1 typical drop (placeholder estimate)
Ceiling effect of GLP-1
GLP-1 lowering has a ceiling; very high HbA1c may exceed it.
Insulin's unlimited titration
Insulin dose can be titrated upward with no pharmacologic ceiling.
How Much Insulin-Secreting Capacity Remains
GLP-1 agonists need residual beta-cell function to work well.
- >60%: Well-preserved (GLP-1 mechanism intact)
- 30–60%: Moderately reduced (GLP-1 response weaker)
- <30%: Severely depleted (favors insulin replacement)
- C-peptide: Marker used (placeholder proxy measure)
GLP-1 mechanism dependency
GLP-1 stimulates the pancreas; an empty reserve limits benefit.
Insulin bypasses the pancreas
Insulin works regardless of remaining beta-cell secretory capacity.
Established Cardiovascular Disease Shifts the Balance
GLP-1 agonists carry proven cardiovascular outcome benefits.
- Positive: CV outcome trials (placeholder trial summary)
- ~14%: MACE reduction (placeholder relative risk)
- Loss: Weight effect (GLP-1 vs. insulin gain)
- Lower: Hypoglycemia risk (with GLP-1 vs. insulin)
Proven cardioprotection
Large trials show GLP-1 agonists reduce major cardiac events.
Insulin is CV-neutral
Insulin controls glucose but offers no independent cardiac benefit.
Three Factors, One Weighted Recommendation
HbA1c, beta-cell reserve, and CV risk combine into a verdict.
- Low score: GLP-1 favored (good reserve, CVD present)
- High score: Insulin favored (high HbA1c, low reserve)
- Mid score: Either reasonable (mixed or balanced factors)
- Shared decision: Real-world practice (placeholder clinical note)
Weighing, not ranking
No single factor decides alone; all three are weighed together.
A living decision
Recommendation shifts as HbA1c, reserve, or risk profile changes.